Number of patients with adverse events among 59 lymphoma patients stratified by randomization
| . | ALN (n = 30), n (%) . | Placebo (n = 29), n (%) . |
|---|---|---|
| Any AEs | 19 (63.3) | 15 (51.7) |
| Any serious AE | 15 (50.0) | 14 (48.3) |
| AE related to infection | 6 (20.0) | 9 (31.0) |
| AE related to upper GI tract | 7 (23.3) | 2 (6.9) |
| AE related to lower GI tract | 3 (10.0) | 3 (10.3) |
| AE related to renal toxicity | 1 (3.3) | 2 (6.9) |
| Other AEs | 12 (40.0) | 8 (27.6) |
| AE grade 1 to 2 related to study drug | 3 (10.0) | 1 (3.4) |
| AE grade 3 to 4 related to study drug | 0 (0.0) | 1 (3.4) |
| AE resulting in termination of study drug | 1 (3.3) | 2 (6.9) |
| . | ALN (n = 30), n (%) . | Placebo (n = 29), n (%) . |
|---|---|---|
| Any AEs | 19 (63.3) | 15 (51.7) |
| Any serious AE | 15 (50.0) | 14 (48.3) |
| AE related to infection | 6 (20.0) | 9 (31.0) |
| AE related to upper GI tract | 7 (23.3) | 2 (6.9) |
| AE related to lower GI tract | 3 (10.0) | 3 (10.3) |
| AE related to renal toxicity | 1 (3.3) | 2 (6.9) |
| Other AEs | 12 (40.0) | 8 (27.6) |
| AE grade 1 to 2 related to study drug | 3 (10.0) | 1 (3.4) |
| AE grade 3 to 4 related to study drug | 0 (0.0) | 1 (3.4) |
| AE resulting in termination of study drug | 1 (3.3) | 2 (6.9) |